Technology Landscape, Trends and Opportunities in the Global Neuroprosthetic Market

The technologies in neuroprosthetic has undergone significant change in recent years, with cochlear implant based neuroprosthetic to spinal cord stimulation based neuroprosthetic. The rising wave of new technologies such as vagus nerve stimulation and spinal cord stimulation technology are creating significant potential for advanced neuroprosthetic devices in various medical platforms due to its benefits of reduction in the frequency of seizures and/or less medication with anti-seizure drugs.

In neuroprosthetic market, various technologies such as deep brain stimulation, vagus nerve stimulation, spinal cord stimulation, sacral nerve stimulation technologies are used in the motor neuron disorders, physiological disorders, and cognitive disorders applications. Increasing prevalence of neurological diseases such as traumatic brain injury, stroke, Parkinson’s disease, rise in geriatric population, and increase in healthcare expenditure are creating new opportunities for various neuroprosthetic technologies.

Some of the latest technological developments by various countries in the neuroprosthetic market are as follows:

• United States: Medtronic and Abbott are leading initiatives in neuroprosthetic technology. Medtronic has announced advancements in deep brain stimulation (DBS) technology, with the development of closed-loop systems for personalized treatment of movement disorders like Parkinson's disease. Abbott has introduced innovative spinal cord stimulation (SCS) devices with advanced programming capabilities for chronic pain management.
• Germany: NeuroPace and Boston Scientific are investing in neuroprosthetic innovation. NeuroPace specializes in vagus nerve stimulation (VNS) systems for epilepsy management, with recent developments in closed-loop technology for seizure prediction and prevention. Boston Scientific has introduced sacral nerve stimulation (SNS) devices for bladder and bowel control, leveraging advanced stimulation algorithms for improved efficacy.
• Switzerland: LivaNova and SensArs are driving neuroprosthetic advancements. LivaNova specializes in DBS therapy for treatment-resistant depression, with recent developments in closed-loop neuromodulation systems. SensArs focuses on spinal cord stimulation (SCS) technology for restoring movement in individuals with spinal cord injuries, with innovative electrode designs for targeted stimulation.

This report analyzes technology maturity, degree of disruption, competitive intensity, market potential, and other parameters of various technologies in the neuroprosthetic market. Some insights are depicted below by a sample figure. For more details on figures, the companies researched, and other objectives/benefits on this research report, please download the report brochure.



The study includes technology readiness, competitive intensity, regulatory compliance, disruption potential, trends, forecasts and strategic implications for the global neuroprosthetic technology by application, technology, and region as follows:

Technology Readiness by Technology Type

Competitive Intensity and Regulatory Compliance

Disruption Potential by Technology

Trends and Forecasts by Technology Type [$M shipment analysis from 2018 to 2030]:

• Deep Brain Stimulation
• Vagus Nerve Stimulation
• Spinal Cord Stimulation
• Sacral Nerve Stimulation

Technology Trends and Forecasts by Application [$M shipment analysis from 2018 to 2030]:

• Motor Neuron Disorders
  • Deep Brain Stimulation
  • Vagus Nerve Stimulation
  • Spinal Cord Stimulation
  • Sacral Nerve Stimulation
• Physiological Disorders
  • Deep Brain Stimulation
  • Vagus Nerve Stimulation
  • Spinal Cord Stimulation
  • Sacral Nerve Stimulation
• Cognitive Disorders
  • Deep Brain Stimulation
  • Vagus Nerve Stimulation
  • Spinal Cord Stimulation
  • Sacral Nerve Stimulation

Technology Trends and Forecasts by Region [$M shipment analysis for 2018 to 2030]:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
• Asia Pacific
  • Japan
  • China
  • South Korea
  • India
• The Rest of the World

Latest Developments and Innovations in the Neuroprosthetic Technologies

Companies/ Ecosystems

Strategic Opportunities by Technology Type

Some of the neuroprosthetic companies profiled in this report include Medtronic, Boston Scientific, and Cyberonics.

Below are the latest technological developments from top companies in the neuroprosthetic market:

• Medtronic recently announced the FDA approval of its Percept™ PC Deep Brain Stimulation (DBS) system for Parkinson's disease. The Percept™ PC system features BrainSense™ technology, allowing for brain signals to be recorded simultaneously with stimulation to provide more personalized therapy and insights into disease management.
• LivaNova launched its SenTiva® device for Vagus Nerve Stimulation (VNS) therapy in Europe. SenTiva® features the latest technology advancements, including the ability to detect and log events such as seizures, providing valuable data for patient management and treatment optimization.
• Abbott introduced its Proclaim™ XR SCS system with BurstDR™ stimulation, designed to provide long-lasting pain relief for patients suffering from chronic pain. The Proclaim™ XR system offers personalized therapy options and improved battery longevity, enhancing patient comfort and convenience.
• Axonics Modulation Technologies received FDA approval for its r-SNM® System for Sacral Neuromodulation (SNM) therapy. The r-SNM® System offers a miniaturized implantable neurostimulator with a long-lived, rechargeable battery, providing long-term relief for patients with overactive bladder and bowel dysfunction.

This report answers following 9 key questions:
Q.1 What are some of the most promising and high-growth technology opportunities for the neuroprosthetic market?
Q.2 Which technology will grow at a faster pace and why?
Q.3 What are the key factors affecting dynamics of different technologies? What are the drivers and challenges of these technologies in neuroprosthetic market?
Q.4 What are the levels of technology readiness, competitive intensity and regulatory compliance in this technology space?
Q.5 What are the business risks and threats to these technologies in neuroprosthetic market?
Q.6 What are the latest developments in neuroprosthetic technologies? Which companies are leading these developments? 
Q.7 Which technologies have potential of disruption in this market?
Q.8 Who are the major players in this neuroprosthetic market? What strategic initiatives are being implemented by key players for business growth?
Q.9 What are the strategic growth opportunities in this neuroprosthetic technology space?